Double Your Drug Success Rate

We Deliver Understanding of the Genomic Drivers of Every Disease for Pharma

“Pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approval.”

(King et al. 2019)

WITH MASTERMIND GENOMIC LANDSCAPES…


<strong>EXPAND GENETIC DISCOVERY</strong>

EXPAND GENETIC DISCOVERY

AI and Machine Learning more quickly
and comprehensively identify
the molecular drivers of disease

<strong>STRATIFY CLINICAL TARGETS</strong>

STRATIFY CLINICAL TARGETS

Comprehensive Genomic Landscapes
guide biomarker selection for
clinical trial segregation criteria

<strong>ACCELERATE CDx DEVELOPMENT</strong>

ACCELERATE CDx DEVELOPMENT

Genetic Evidence identifies genomic biomarkers to double companion diagnostic submission success

Genomenon improves drug discovery by accelerating genomic understanding

TALK TO US ABOUT YOUR GENOMIC DATA NEEDS

Our curated Genomic Landscapes provide immediate insight into the genomic evidence for every phenotype, therapy, disease, gene, and variant.
Pharmaceutical and biotech companies license Genomenon’s comprehensive Genomic Landscapes to identify and prioritize genomic biomarkers for drug discovery, clinical trial candidate selection, and CDx submission.

With You Through the Development Process

Genomenon’s Curated Genomic Datasets help Pharma at all stages of drug development

TALK TO US ABOUT YOUR GENETIC DATA APPLICATION

Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

Genomenon’s methodology improved the efficiency and completeness of our literature review process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.